40 completed, 9 terminated, 7 recruiting, 6 active not recruiting. 68 Phase 1, 25 Phase 2.
Follow Cellcept: new trials by email Literature Review of Cellcept trials Research Report on Cellcept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-11-09 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1 | Terminated | Washington University School of Medicine | 17 | 2023-02-27 | 2024-12-05 |
| Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy - Astrocytoma, Glioblastoma | Phase 1 | Active not recruiting | Northwestern University | 86 | 2022-08-08 | 2026-08-26 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
| Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide - Hematopoietic and Lymphoid System Neoplasm | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 25 | 2020-03-13 | 2026-07-16 |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2019-07-10 | 2026-06-22 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 74 | 2017-07-30 | 2026-06-10 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine - Secondary Myelofibrosis | Phase 1 | Active not recruiting | City of Hope Medical Center | 22 | 2017-06-21 | 2026-08-21 |
| Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT Fludarabine, Busulfan, Cyclophosphamide - Non-Hodgkin's Lymphoma, Acute Leukemia in Remission | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2017-01-31 | 2021-09-16 |
| Treg Therapy in Subclinical Inflammation in Kidney Transplantation Polyclonal Regulatory T Cells, Everolimus, Tacrolimus - Kidney Transplant, Adult Living Donor Kidney Transplant Recipients | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 32 | 2016-09-20 | 2026-09-24 |
| Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Cyclophosphamide, Fludarabine, Tacrolimus - Lupus Erythematosus, Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2016-09-13 | 2019-10-02 |
| Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease Alemtuzumab, Cyclophosphamide, Mycophenolate mofetil - Sickle Cell Disease | Phase 1 | Terminated | Washington University School of Medicine | 1 | 2016-04-26 | 2022-02-14 |
Showing 20 of 68. Sign in to see all of them.
Leukemia, Myeloid, Acute (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Hodgkin Disease (14) · Leukemia, Myelomonocytic, Chronic (13) · Lymphoma, Non-Hodgkin (13) · Myelodysplastic Syndromes (12) · Multiple Myeloma (11) · Anemia, Refractory, with Excess of Blasts (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8) · Myeloproliferative Disorders (7) · Graft vs Host Disease (6) · Leukemia, Biphenotypic, Acute (6) · Lymphoma (6)
Fred Hutchinson Cancer Center (21) · M.D. Anderson Cancer Center (10) · Dr. Reddy's Laboratories Limited (4) · City of Hope Medical Center (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Northwestern University (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Stanford University (2) · Washington University School of Medicine (2) · Astellas Pharma Inc (1) · Boston University (1) · Case Comprehensive Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · Northwell Health (1)
United States (58) · Italy (5) · India (4) · Germany (3) · New Zealand (1) · Russia (1) · South Korea (1)
Brenda Sandmaier (6) · David Maloney (3) · Elizabeth Shpall, MD (2) · Johnnie Orozco (2) · Phuong Vo (2) · T Gitanjali, MD (2) · Amandeep Salhotra (1) · Ann Woolfrey (1) · Brandon Triplett, MD (1) · Brenda M. Sandmaier (1) · Chitra Hosing (1) · Colleen Delaney (1) · Damian Green (1) · Daniel Morgensztern, M.D. (1)
PMID 32499241, PMID 18035553, PMID 18424759, PMID 18554762, PMID 18557726, PMID 19066739, PMID 19786617, PMID 20236866, PMID 21868572, PMID 23234514, PMID 23607606, PMID 23903014, PMID 25778529, PMID 29353109, PMID 30335787, PMID 31397274, PMID 31582553, PMID 32710011, PMID 33635333, PMID 34312462, PMID 37939122
P30CA015704 (15), P01CA078902 (5), P01CA044991 (4), P01CA018029 (2), P01CA148600 (2), P30CA033572 (2), K12HD043494 (1), P01CA049639 (1), P01HL036444 (1), P01HL122173 (1), P30CA014599 (1), P30CA016672 (1), P30CA036727 (1), P30CA043703 (1), P30CA060553 (1)